October 17, 2025

Emergent BioSolutions Inc. (EBS) Investor Outlook: Potential 43% Upside Amid Volatile Healthcare Landscape

Emergent BioSolutions Inc. (NYSE: EBS) is a key player in the healthcare sector, specifically within the niche of specialty and generic drug manufacturing. With a market..

Verastem, Inc. (VSTM) Stock Analysis: Exploring a 62.99% Potential Upside in the Biotech Sector

Verastem, Inc. (VSTM) has captured the attention of investors with its promising pipeline in the oncology sector, combined with a compelling potential upside of 62.99%. As..

Personalis, Inc. (PSNL) Stock Analysis: Navigating the Healthcare Sector with Strong Buy Ratings

Personalis, Inc. (NASDAQ: PSNL) is an intriguing player in the healthcare sector, particularly within the diagnostics and research industry. Headquartered in Fremont, California, this company specializes..

Altimmune, Inc. (ALT) Stock Analysis: Exploring a Promising 322.74% Potential Upside in Biotech

For individual investors seeking opportunities in the healthcare sector, Altimmune, Inc. (NASDAQ: ALT) offers a fascinating case study in the biotechnology space. With a market capitalization..

Tourmaline Bio, Inc. (TRML) Stock Analysis: Navigating Growth in the Biotech Sector

Tourmaline Bio, Inc. (NASDAQ: TRML), a burgeoning name in the biotechnology sector, has been capturing investor attention with its promising pipeline aimed at treating complex immune..

Bicycle Therapeutics (BCYC) Investor Outlook: Uncovering a 176% Potential Upside in Biotech Innovation

Bicycle Therapeutics plc (NASDAQ: BCYC), a clinical-stage pharmaceutical company, stands at the forefront of pioneering new classes of medicines for diseases underserved by existing therapies. With..

Prothena Corporation plc (PRTA) Stock Analysis: Potential 28.84% Upside Amidst Promising Clinical Pipeline

Prothena Corporation plc (NASDAQ: PRTA), a Dublin-based biotechnology company, is capturing investor attention with its innovative approach to tackling diseases caused by protein dysregulation. Despite recent..

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: A 215% Potential Upside Awaits Patient Investors

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN), a burgeoning player in the healthcare sector, is making significant strides in the biotechnology industry. With a market capitalization of..

LifeMD, Inc. (LFMD) Stock Analysis: Exploring a Potential 100% Upside as Telehealth Expands

LifeMD, Inc. (LFMD) is a burgeoning player in the healthcare sector, specifically within the health information services industry. With a market cap of $304.89 million, LifeMD..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis: A Biotech Innovator with 137.90% Potential Upside

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a promising player in the biotechnology sector, is grabbing attention with its cutting-edge research in inflammatory bowel disease (IBD) and a..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Exploring a 198% Upside Potential in Biotechnology

Nurix Therapeutics, Inc. (NASDAQ: NRIX), a San Francisco-based biotechnology company, is capturing investor attention with its innovative approach to drug discovery and development. As a clinical-stage..

Sonida Senior Living, Inc. (SNDA) Stock Analysis: A Look at Growth Amidst Financial Challenges

Sonida Senior Living, Inc. (NASDAQ: SNDA), a key player in the healthcare sector, operates senior housing communities across the United States. With a market capitalization of..

Immunome, Inc. (IMNM) Stock Analysis: A Biotech Firm with a 45% Upside Potential

Investors interested in the biotechnology sector should pay close attention to Immunome, Inc. (NASDAQ: IMNM), a clinical-stage company focused on innovative cancer therapies. With a current..

AngioDynamics, Inc. (ANGO) Stock Analysis: A 57.85% Potential Upside Sparks Investor Interest

AngioDynamics, Inc. (NASDAQ: ANGO) is making waves in the healthcare sector with its innovative medical technology solutions. Despite a challenging financial landscape, the company presents a..

Replimune Group, Inc. (REPL) Stock Analysis: Navigating Biotech’s Volatile Waters with a Precise Focus on Cancer Immunotherapy

Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company, is making strides in the healthcare sector with its innovative approach to oncolytic immunotherapies aimed at treating..

EyePoint Pharmaceuticals, Inc. (EYPT) Stock Analysis: Exploring the 197.98% Upside Potential

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is capturing the attention of investors with its compelling growth potential and innovative approach in the biotechnology sector. Headquartered in Watertown,..

Akso Health Group (AHG) Stock Analysis: Navigating a 415.8% Revenue Growth in China’s Medical Distribution Sector

Akso Health Group (NASDAQ: AHG) is making waves in the healthcare sector, particularly within the medical distribution industry in China. With a market capitalization of $911.67..

Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Promising 62.73% Upside in the Biotech Arena

Oruka Therapeutics, Inc. (ORKA), a clinical-stage biopharmaceutical company based in Menlo Park, California, is making waves in the biotechnology sector by focusing on innovative monoclonal antibody..

Humacyte, Inc. (HUMA): Analyst Ratings Highlight a 387% Potential Upside for Innovative Biotech Pioneer

Humacyte, Inc. (NASDAQ: HUMA) stands out in the biotechnology sector with its cutting-edge approach to developing off-the-shelf, implantable bioengineered human tissues. As the healthcare landscape continues..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating a Challenging Landscape with -11.70% Revenue Growth

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), a prominent player in the biotechnology sector, presents a unique case study for investors considering the intersection of innovation and..

Search

Funds

October 17, 2025

Search

Funds

October 17, 2025

FTSE 100

Funds